Halloween graveyard
Biotech

The 2026 Biotech Graveyard

Join us for our annual ritual as we remember the biotechs lost this year to a tough funding environment or disappointing clinical trial readouts.
IPO initial public offering markets raise financing

Bambusa shoots past IPO targets as Aspen trims offering

Oct 30, 2026 4:01am
Sanofi

Sanofi mulling ‘moonshot’ M&A targets to survive Dupixent cliff

Oct 30, 2026 3:27am
cardboard box with office belongings and a desk chair

Molecular Partners plots 44% staff cutback in radiotherapy pivot

Oct 30, 2026 3:18am
Lilly

Lilly scraps ph. 2 Alzheimer's program after drug falls short

Oct 29, 2026 2:09pm
Merck Co
Favicon Fierce Pharma

For Merck, 2027 is ‘another year of investment’

Oct 29, 2026 11:23am
More News

BMS walks away from $80M neurodegeneration bet after phase 1

Oct 29, 2026 10:53am

BioMarin inks up to $475M deal to challenge Fabry ERT incumbents

Oct 29, 2026 10:13am

Flagship unites 3 biotech platforms in AI player Etcelera

Oct 29, 2026 9:27am
Fierce Pharma

Novartis refreshes myelofibrosis bid as Geron flops in ph. 3

Oct 29, 2026 8:15am